Etrolizumab-rhuMAb-Beta7-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEEtrolizumabCat.No.:HY-P9984CASNo.:1044758-60-2Synonyms:rhuMAbBeta7;RG7413;PRO145223作?靶點:Integrin作?通路:Cytoskeleton儲存?式:PleasestoretheproductundertherecommendedconditionsintheCertificateofAnalysis.BIOLOGICALACTIVITY?物活性Etrolizumab(rhuMAbBeta7)?種腸道選擇性抗-β7整合素單克隆抗體。Etrolizumab針對α4β7和αEβ7整合素的β7亞的特異性靶向藥物。Etrolizumab可?于炎癥性腸病(IBD)的研究。IC50&Targetα4β7αEβ7體外研究Etrolizumab(rhuMAbBeta7)bindstheβ7subunitofbothα4β7andαEβ7integrinswithhighaffinity,withKdvaluesof18nM,1800pM,181pM,116pM,57pM,31.7pM,and25.7pMforHumanα4β7,HumanαEβ7-293,Mouseα4β7-38C13,Humanα4β7-293,RabbitPBLs,HumanPBLs,andCynoPBLs,respectively[1].Etrolizumab(RPMI8866cellsandαEβ7-293cells)blockstheinteractionofα4β7withitscognateligandsMAdCAM-1andVCAM-1withIC50valuesof0.075and0.089nM,respectively,andblockstheinteractionbetweenαEβ7anditsligandE-cadherinwithanIC50valueof3.96nM[1].體內(nèi)研究Etrolizumab(rhuMAbBeta7;5mg/kg;i.v.;once;normalfemaleBALB/cmice)decreasesβ7integrinsonTlymphocytes[2].Etrolizumab(200μg(100μL);i.p.;once)inhibitslymphocytehomingintheCD45RBhighTcell-reconstitutedSCIDmousemodelofcolitis[2].AnimalModel:NormalfemaleBALB/cmice(17-21g)[2]Dosage:5mg/kgAdministration:Intravenousinjection;onceResult:Had98.3%ofintraepithelialCD8+T-cellβ7integrinreceptorsand90.0%of1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEintraepithelialCD4+T-cellβ7integrinreceptorsafter24h.AnimalModel:SCIDmousemodelofcolitis[2]Dosage:200μg(100μL)Administration:Intraperitonealinjection;onceResult:Blockedlymphocyterecruitmentandhomingtotheinflamedcolon.REFERENCES[1].TangMT,et,al.Reviewarticle:nonclinicalandclinicalpharmacology,pharmacokineticsandpharmacodynamicsofetrolizumab,ananti-β7integrintherapyforinflammatoryboweldisease.AlimentPharmacolTher.2018Jun;47(11):1440-1452.[2].StefanichEG,et,al.Ahumanizedmonoclonalantibodytargetingtheβ7integrinselectivelyblocksintestinalhomingofTlymphocytes.BrJPharmacol.2011Apr;162(8):1855-70.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuse